the next three names are biotech, it's celgene, regeneron and gilead.e four red hot biotechs look like from a chart perspective? okay. let's start with the best-performing biotech, which is celgene. that's the maker of revlamid for multiple myeloma. check out this stock, as you can see, celgene has had an amazing run since mid august, okay? and lang points out that this run has happened on very high volume. see, there's the volume spike, okay. especially on the up days. remember, volume is like a lie detector for technicians. the stronger it is, the more likely a move is telling the truth. because high volume indicates big boys are doing some buying. that's what makes the stock anointed, when it has massive sponsorship. and the big hedge funds and mutual funds use any weakness to accumulate the stock, which is what i'm saying. after the fed meeting could get weakness, think of this stock. what else is happening to celgene? looking at the moving average convergence divergence, that's the macd at the bottom of the chart. this is a directional momentum ind

gilead is all about hepatitis c.ioagain idec, that stock is all about multiple sclerosis treatments that are taking off. and regeneron has the alternative for those who can't take traditional statens. they're going to have perfect performance, so the money is going to flow in. next up, linkedin, rallied $7.32 today. linkedin is an amazing company, it blew away the numbers. itting sell rates the revenue, no-brainer for these stock managers. how about these names, the cult stocks that people buy because they love the product. amazon up $5.40. netflix, yes, tesla. they're overvalued by any stretch of the imagination. people like to shop on amazon, they like netflix and they love the idea of driving a tesla. what can i say, in a bull market there are always stocks like these. the three musketeers of this market. mythical ones, all swash buckling anointed stocks. you have to get out of the way at the end of the corner. did you really think that price line, up 14.29 wouldn't be on this list? come on. here's the cheaper way

when we hear the word pipeline we think of celgene, gilead. we should think under armour? >> no question. we want to be open source innovation. number one, first of all, within our r & d group, the 40-some odd people we have at campus at our headquarters are thinking and utilizing and leveraging some of the partners we have around there, people like darpa and icutel and lockheed martin and other relationships that we can leverage in our area. it's not saying all the great ideas come from silicon valley. so we look at those ideas, get inspired by those companies and look to form partnerships where we can. at the same time, we also want to embrace the entire cloud. we don't want under armour just to be 40 people within our walls coming up with the next big idea. if you're an entrepreneur, if you're an innovator, a 23 year-old kid with a better idea of a cotton t-shirt, instead of trying to start that company yourself, why not bring that idea to us, see if we can use our fabric expertise, manufacturing expertise, our ability to tell stories and get it out there from a distrib

gilead, cell gene, amgen. another bright spot, internet stocks. yahoo! hitting a five-year high after marissa mayer's up beat comments. those are some of the big winners fueling the nasdaq right now. scott and maria? >> apple shares rebounding today after the cool reception yesterday after the new iphones were released. investors may have heard carl icahn tell yesterday in an exclusive interview that he wants to buy more apple. take a listen. >> i think apple is is just a no brainer. it's extremely cheap. i'm just looking at the numbers. >> so should you follow icahn and pick up more apple? we start talking numbers, looking at apple today. on the technical side of the story, richard ross. global technical strategist. on the fundament ams, market liktenfeld. good to see you guys. thanks for joining us. mark, how does apple look from a fundamental perspective? >> one thing we know, maria, carl icahn's mama didn't raise no dummies. he's got a key eye for value. that's exactly what apple is. a great value stock here. trades at 11 times forward earnings. six

two years ago, gilead paid $12 billion for pharmasset, a company with no revenue, just a handful of employeesand it was right to do, because that's the hep c cure. we hope. if things go well, say the fda approves this drug before the end of the year and the launch goes faster than expected. pharmacyclics could rally hard in the not too distant future. before you get super excited, let me remind you, this is speculation, and there are a lot of things that could go wrong. first of all, the stock is up 125% year-to-date so a long way to fall if it stumbles. second, it's possible its outstanding drug won't get fda approval in which case the entire story i told falls apart. now i don't expect that to happen. but when you play fda roulette, you need to be prepared for the worst. third, even if it gets approved, the launch might go slower than expected, and, again, not something i believe will happen, it will put a serious damper on the stock if it does. last but not least, competition. do you know there are currently 159 active clinical trials for chronic lymphocytic leukemia, 270 trials going on i

gilead, biogen, reagainer ron, celgene. seeing breakdown in financials. this worries me.n the last month it started slipping. now notably underperforming. trading activity in citi group. this has been going on for several weeks now. you see the decline. here what happens i'm worried about this week. we don't have a lot of positive catalysts. we're enthralled to washington and traders hate it when washington moves the stock market. lack of leadership here. yellen, cancel the speech for october 1stst in new york, bernanke on the sidelines and deal with the clean spending bill whether it's going to pass the house and senate. it's not a lot of positive catalysts for the market and it's showing in today's action. >> a heck of a month so far. amazing september. thanks, bob. >>> problems for carnival cruise lines, the ship christened by kate middleton taken out of service for repair. experienced a power outage sailing in the mediterranean. it does not know whether the ship will be ready for its next scheduled departure on september 27th. carnival ed scheduled to report earnings

in the biotech space, thanks to upbeat earning, cellgene, gilead had better than 20% over the past threerm over the past three months as well. back to you. >> seema, thank you so much. >>> as the october 1st budge oat deadline approaches, the next big debate in washington will be the debt ceiling and where to cut government spending. the next guest is proposing an amendment that exempts the defense department from sequestration if the u.s. strikes in syria. u.s. senator james inhofe of oklahoma joins us this morning from washington. senator, it's great to see you. good morning. >> thanks, carl. good morning to you. >> talk about the collision between foreign and domestic policy. why is this important? >> well, first of all, i'm opposed to the president's program of military intervention in syria. but the reason is a different reason than most of the rest of them. that gets right down to the question you asked. our military's in -- this president has decimated our military in the last 4 1/2 years. and you remember that first budget that he had, he did away with our only fifth generation f